Our top pick for
Beginners
Karyopharm Therapeutics Inc is a biotechnology business based in the US. Karyopharm Therapeutics shares (KPTI) are listed on the NASDAQ and all prices are listed in US Dollars. Karyopharm Therapeutics employs 442 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Karyopharm Therapeutics
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – KPTI – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Karyopharm Therapeutics stock price (NASDAQ: KPTI)
Use our graph to track the performance of KPTI stocks over time.Karyopharm Therapeutics shares at a glance
Information last updated 2022-06-24.
| Latest market close | $5.17 |
|---|---|
| 52-week range | $4.02 - $14.73 |
| 50-day moving average | $5.92 |
| 200-day moving average | $6.98 |
| Wall St. target price | $12.38 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.42 |
Buy Karyopharm Therapeutics shares from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.1 - 6 of 6
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Karyopharm Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Karyopharm Therapeutics price performance over time
Historical closes compared with the close of $5.17 from 2022-06-24
| 1 week (2022-06-17) | 16.44% |
|---|---|
| 1 month (2022-05-22) | N/A |
| 3 months (2022-03-25) | -29.27% |
| 6 months (2021-12-22) | N/A |
| 1 year (2021-06-25) | -52.96% |
|---|---|
| 2 years (2020-06-26) | -71.93% |
| 3 years (2019-06-26) | 6.06 |
| 5 years (2017-06-26) | 9.52 |
Karyopharm Therapeutics financials
| Revenue TTM | $234.2 million |
|---|---|
| Gross profit TTM | $57.4 million |
| Return on assets TTM | -17.33% |
| Return on equity TTM | -891.05% |
| Profit margin | -46.14% |
| Book value | $0.68 |
| Market capitalisation | $410.6 million |
TTM: trailing 12 months
Karyopharm Therapeutics share dividends
We're not expecting Karyopharm Therapeutics to pay a dividend over the next 12 months.
Karyopharm Therapeutics share price volatility
Over the last 12 months, Karyopharm Therapeutics's shares have ranged in value from as little as $4.02 up to $14.73. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Karyopharm Therapeutics's is -0.1665. This would suggest that Karyopharm Therapeutics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Karyopharm Therapeutics has bucked the trend.
Karyopharm Therapeutics overview
Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Frequently asked questions
What percentage of Karyopharm Therapeutics is owned by insiders or institutions?Currently 8.855% of Karyopharm Therapeutics shares are held by insiders and 90.972% by institutions. How many people work for Karyopharm Therapeutics?
Latest data suggests 442 work at Karyopharm Therapeutics. When does the fiscal year end for Karyopharm Therapeutics?
Karyopharm Therapeutics's fiscal year ends in December. Where is Karyopharm Therapeutics based?
Karyopharm Therapeutics's address is: 85 Wells Avenue, Newton, MA, United States, 02459 What is Karyopharm Therapeutics's ISIN number?
Karyopharm Therapeutics's international securities identification number is: US48576U1060 What is Karyopharm Therapeutics's CUSIP number?
Karyopharm Therapeutics's Committee on Uniform Securities Identification Procedures number is: 48576U106
More guides on Finder
-
How to buy LeeWay Services stock when it goes public
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
-
How to buy Nano Labs (NA) stock when it goes public
Everything we know about the Nano Labs IPO, plus information on how to buy in.
-
How to buy Warrantee (WRNT) stock when it goes public
Everything we know about the Warrantee IPO, plus information on how to buy in.
-
How to buy Treasure Global (TGL) stock when it goes public
Everything we know about the Treasure Global IPO, plus information on how to buy in.
-
How to buy BIOLIFE4D (SAVU) stock when it goes public
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
-
How to buy NYIAX (NYX) stock when it goes public
Everything we know about the NYIAX IPO, plus information on how to buy in.
-
How to buy Adamas One Corp (JEWL) stock when it goes public
Everything we know about the Adamas One Corp IPO, plus information on how to buy in.
-
How to buy Glucose Health (GLUC) stock when it goes public
Everything we know about the Glucose Health IPO, plus information on how to buy in.
-
How to buy Boustead Wavefront (BOUW) stock when it goes public
Everything we know about the Boustead Wavefront IPO, plus information on how to buy in.
-
How to buy ParaZero Technologies (PRZO) stock when it goes public
Everything we know about the ParaZero Technologies IPO, plus information on how to buy in.
Ask an Expert